P451 - EFFECTS OF NANO-NARINGENIN ON HEPATIC INFLAMMATION AND STEATOSIS IN MICE

P451

EFFECTS OF NANO-NARINGENIN ON HEPATIC INFLAMMATION AND STEATOSIS IN MICE

K. Uçar Baş¹, A. Alpaslan^2,*, Z. Göktaş²

¹Osmaniye Korkut Ata University, Osmaniye, ²Hacettepe University, Ankara, Türkiye

Rationale: Naringenin (N) has been suggested to exert potential protective effects against liver steatosis and inflammation through its antioxidant and anti-inflammatory properties. In this study, we aimed to investigate the effects of intravenously administered nano-naringenin on liver steatosis and inflammation-related markers in female C57BL/6J mice.

Methods: Twenty-four female C57BL/6J mice were randomly allocated into four groups: free-N (20 µM), nano-N (20 µM), void, and control (PBS). All animals were fed a high-fat diet (60% kcal from fat) for 10 weeks to induce hepatic steatosis. Subsequently, for an additional 10 weeks, the dietary regimen continued in parallel with intravenous administration of the respective treatments via tail vein injection. At the end of the intervention, liver tissues were collected to measure the protein concentrations of TNF-α (a pro-inflammatory cytokine), FXR, and SREBP-1c (key regulators of lipid metabolism and hepatic steatosis) using ELISA. Statistical analyses were conducted using SPSS software.

Results: There were no statistically significant differences in the protein concentrations of TNF-α, FXR, or SREBP-1c among the treatment groups (p>0.05). Among these, the control group exhibited the highest TNF-α level, whereas the nano-naringenin group showed the lowest. Similarly, FXR levels peaked in the control group and were lowest in the free-naringenin group. For SREBP-1c, the highest concentration was detected in the control group, while the void group had the lowest value.

Conclusion: Naringenin may have a modest effect on hepatic inflammation and lipid metabolism. Although differences were not statistically significant, lower TNF-α and FXR levels in treatment groups suggest potential benefits. Further studies are needed to confirm these findings.

Disclosure of Interest: None declared